Navigation Links
Hospira Reports First-Quarter 2009 Results
Date:4/28/2009

-- Affirms Sales Projection and Narrows Earnings Guidance to Upper End of Range for 2009 --

LAKE FOREST, Ill., April 28 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today reported results for the first quarter ended March 31, 2009. Net sales for the quarter were $860 million, and adjusted* diluted earnings per share were $0.60. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.)

"Hospira delivered on its commitments in the first quarter, generating solid sales and earnings growth in a period marked by continued economic uncertainty," said Christopher B. Begley, chairman and chief executive officer. "Looking forward, we believe the results of our strategic investments and our focus on execution position us well to deliver our financial commitments for 2009. In addition, we are driving operational excellence through our optimization initiatives under Project Fuel, which will create long-term, sustainable growth and increased shareholder value."

First-Quarter 2009 Results

The following table highlights selected financial results for the first quarter of 2009 compared to the same period in 2008:

    In $ millions,              GAAP                     Adjusted*
     except per          Three Months Ended         Three Months Ended
     share amounts            March 31,                  March 31,
                          ----------------     %     ----------------     %
                           2009      2008   Change    2009      2008   Change
                          ------    ------  ------   ------    ------  ------
    Net Sales             $859.7    $888.7   (3.3)%    n/a       n/a     n/a
    Gross Profit          $319.6    $317.0    0.8 %  $339.6    $337.5    0.6 %
    Income from
     Operations           $114.7    $111.7    2.7 %  $149.9    $145.2    3.2 %
    Diluted EPS            $1.03     $0.41  151.2 %   $0.60     $0.55    9.1 %

    Statistics (as a % of Net Sales)
    --------------------------------
    Gross Profit            37.2 %    35.7 %           39.5 %    38.0 %
    Operating Income        13.3 %    12.6 %           17.4 %    16.3 %


Results under U.S. Generally Accepted Accounting Principles (GAAP) include items as detailed in the schedules attached to this press release, including a $0.57 benefit to first-quarter 2009 GAAP diluted earnings per share from the settlement of a U.S. Internal Revenue Service audit.

Net sales decreased 3.3 percent to $860 million in the first quarter of 2009, compared to $889 million in the first quarter of 2008. Growth in Other Pharma in the Americas segment and solid overall performance in Medication Management Systems (MMS), mainly a function of continued penetration of Symbiq(R), were offset by unfavorable foreign currency translation and continued pricing pressure in Specialty Injectable Pharmaceuticals (SIP) in the Europe, Middle East and Africa (EMEA) segment.

Adjusted* operating income increased 3.2 percent to $150 million in the first quarter of 2009, compared to $145 million in the first quarter of 2008. Driving the majority of the increase was improved manufacturing efficiency, with a contribution from favorable volume/mix.

Cash Flow

Cash flow from operations for the first quarter of 2009 was $89 million, compared to the $74 million generated in the same period in 2008.

Capital expenditures decreased to $34 million for the first quarter of 2009, compared to $43 million in the first quarter of 2008, due to the continued impact of capital-spending controls the company put into effect in the second half of 2008.

2009 Projections

Hospira continues to expect net sales for the year to increase approximately 4 to 6 percent on a constant-currency basis. Including the impact of foreign exchange, the company expects net sales to be flat.

Given the continued uncertainty surrounding the approval timing of piperacillin tazobactam, a key generic injectable pharmaceutical projected to launch during the year, Hospira has elected to remove sales of the drug from its 2009 projections. Offsetting this impact, the company now expects to receive a benefit from a lower estimated effective tax rate for 2009, as well as anticipated savings from the company's optimization efforts under its Project Fuel initiative. Hospira therefore projects adjusted* diluted earnings per share for full-year 2009 to range between $2.67 to $2.72 per share.

The reconciliation between the projected 2009 adjusted* diluted earnings per share and GAAP diluted earnings per share follows:

       Diluted earnings per share -- adjusted*                  $2.67 - $2.72
                                                                -------------
       Estimated charges related to planned Project
       Fuel initiatives (mid-point range of an estimated
       $0.38 to $0.42 per diluted share for 2009)                      ($0.40)

       Estimated charges related to planned facilities
       initiatives (mid-point of an estimated range of
       $0.10 to $0.12 per diluted share for 2009)                      ($0.11)

       Estimated $53 million for the amortization of
       intangibles related to the Mayne Pharma acquisition             ($0.23)

       Benefit from the settlement of a U.S. income tax audit           $0.57
                                                                -------------
       Diluted earnings per share -- GAAP                       $2.50 - $2.55
                                                                =============

Projections for cash flow from operations, depreciation and amortization, and capital expenditures remain unchanged. The company continues to project that cash flow from operations in 2009 will be in the $565 million to $615 million range. Depreciation and amortization is expected to be between $210 million and $220 million. Capital expenditures are projected to be between $155 million and $175 million.

*Use of Non-GAAP Financial Measures

Non-GAAP financial measures used in this press release are reconciled to the most comparable measures calculated in accordance with GAAP in the schedules attached to this release. For more information regarding these non-GAAP financial measures, please see Hospira's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.

Webcast

Hospira will hold a conference call for investors and media at 8 a.m. Central time on Tuesday, April 28, 2009. A live webcast of the conference call will be available at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup for receiving the webcast. A replay will be available on the Hospira Web site for 30 days following the call.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

               Private Securities Litigation Reform Act of 1995 --
                 A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, and other statements regarding Hospira's goals and strategy. Hospira cautions that these forward-looking statements are subject to risks, uncertainties and assumptions, many of which are beyond Hospira's control, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K, filed with the Securities and Exchange Commission, which is incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

                                  Hospira, Inc.
                   Condensed Consolidated Statements of Income
                                   (Unaudited)
         (dollars and shares in millions, except for per share amounts)

                                                 Three Months Ended
                                                     March  31,
                                                   --------------       %
                                                     2009    2008     Change
                                                   ------  ------     ------
    Net sales                                      $859.7  $888.7     (3.3)%
                                                   ------  ------

    Cost of products sold                           540.1   571.7     (5.5)%
    Restructuring                                     9.4     3.0    213.3 %
    Research and development                         50.0    49.9      0.2 %
    Selling, general and administrative             145.5   152.4     (4.5)%
                                                   ------  ------
        Total operating expenses                    745.0   777.0     (4.1)%
                                                   ------  ------
          Income From Operations                    114.7   111.7      2.7 %

    Interest expense                                 26.9    31.4    (14.3)%
    Other income, net                                (0.3)   (4.1)   (92.7)%
                                                   ------  ------
          Income Before Income Taxes                 88.1    84.4      4.4 %

    Income tax (benefit) expense                    (77.4)   19.0   (507.4)%
                                                   ------  ------
          Net Income                               $165.5   $65.4    153.1 %
                                                   ======  ======

    Earnings Per Common Share:
        Basic                                       $1.04   $0.41    153.7 %
                                                   ======  ======
        Diluted                                     $1.03   $0.41    151.2 %
                                                   ======  ======

    Weighted Average Common Shares Outstanding:
        Basic                                       159.5   158.7      0.5 %
                                                   ======  ======
        Diluted                                     160.6   161.0     (0.2)%
                                                   ======  ======


    Adjusted Gross Profit (1)(2)                   $339.6  $337.5      0.6 %
    Adjusted Income From Operations (1)            $149.9  $145.2      3.2 %
    Adjusted Net Income (1)                         $96.8   $87.9     10.1 %
    Adjusted Diluted Earnings Per Share (1)         $0.60   $0.55      9.1 %


    Statistics (as a % of net sales,
    except for income tax rate):

                                Three Months Ended      Three Months Ended
                                  March 31, 2009          March 31, 2008
                              ----------------------  ----------------------
                               GAAP     Adjusted (1)   GAAP     Adjusted (1)
                              ------    ------------  ------    ------------
    Gross Profit (2)          37.2 %       39.5 %     35.7 %       38.0 %
    Income From Operations    13.3 %       17.4 %     12.6 %       16.3 %
    Net Income                19.3 %       11.3 %      7.4 %        9.9 %
    Income Tax Rate          (87.8)%       21.5 %     22.5 %       25.5 %

    (1) The Non-GAAP financial measures contained in this press release
    (gross profit, income from operations, net income, and diluted Earnings
    Per Share) adjust for items that are unusual or nonrecurring. Unusual or
    nonrecurring items can be highly variable, difficult to predict, and of
    a size that may substantially impact Hospira's reported results for a
    period. Management believes that Non-GAAP financial measures can
    facilitate a complete analysis of Hospira's results of operations,
    particularly in evaluating performance over time. Management uses these
    Non-GAAP financial measures internally in financial planning, to monitor
    business unit performance, and in evaluating management performance.
    Refer to Hospira's filing on Form 8-K of today's date for additional
    information.
    (2) Net sales less Cost of products sold.



                                   Hospira, Inc.
               Reconciliation of GAAP to Non-GAAP Financial Measures
                                    (Unaudited)
                  (dollars in millions, except per share amounts)


    Three months ended March 31, 2009 adjustments and Reconciliation of GAAP
     to Non-GAAP Financial Measures:

                                                    Income
                                        Gross        From       Net    Diluted
                                      Profit (2)  Operations  Income     EPS
                                      ----------  ----------  ------   -------
    GAAP                                $319.6      $114.7    $165.5    $1.03
    Adjustments:
       Project Fuel restructuring and
        optimization charges (A)             -        10.5       6.5     0.04
       Facilities restructuring and
        optimization charges (B)           7.0        11.7       7.7     0.05
       Amortization of Mayne Pharma
        intangible assets (C)             13.0        13.0       9.0     0.05
       Resolution of IRS tax audit
        benefit (D)                          -           -     (91.9)   (0.57)
                                      ----------  ----------  ------   -------
    Adjusted financial measures (1)     $339.6      $149.9     $96.8    $0.60
                                      ==========  ==========  ======   =======

    GAAP results for the three months ended March 31, 2009:
    A -- Project Fuel restructuring and optimization charges include:
         $4.7 million reported in Restructuring, $0.4 million reported in
         Research and Development and $5.4 million reported in Selling,
         general administrative.
    B -- Facilities restructuring and optimization charges include:
         $7.0 million reported in Cost of products sold and $4.7 million
         reported in Restructuring.
    C -- Amortization of Mayne Pharma intangible assets of $13.0 million
         reported in Cost of products sold.
    D -- Resolution of IRS tax audit benefit of $91.9 million reported in
         Income tax (benefit) expense.


    Three months ended March 31, 2008 adjustments and Reconciliation of GAAP
     to Non-GAAP Financial Measures:

                                                    Income
                                        Gross        From       Net    Diluted
                                     Profit (2)   Operations  Income     EPS
                                     -----------  ----------  ------   -------
    GAAP                                $317.0      $111.7    $65.4     $0.41
    Adjustments:
       Facilities restructuring and
        optimization charges (A)           4.4         7.8      5.0      0.03
       Amortization of Mayne Pharma
        intangible assets (B)             15.7        15.7     10.6      0.07
       Integration-related charges (C)     0.4        10.0      6.9      0.04
                                      ----------  ----------  ------   -------
    Adjusted financial measures (1)     $337.5      $145.2    $87.9     $0.55
                                      ==========  ==========  ======   =======

    GAAP results for the three months ended March 31, 2008:
    A -- Facilities restructuring and optimization charges include:
         $4.4 million reported in Cost of products sold, $3.0 million
         reported in Restructuring and $0.4 million reported in Research and
         development.
    B -- Amortization of Mayne Pharma intangible assets of $15.7 million
         reported in Cost of products sold.
    C -- Integration-related charges include: $0.4 million reported in Cost of
         products sold, $0.4 million reported in Research and development and
         $9.2 million reported in Selling, general and administrative.

    (1) The Non-GAAP financial measures contained in this press release
    (gross profit, income from operations, net income, and diluted Earnings
    Per Share) adjust for items that are unusual or nonrecurring. Unusual or
    nonrecurring items can be highly variable, difficult to predict, and of
    a size that may substantially impact Hospira's reported results for a
    period. Management believes that Non-GAAP financial measures can
    facilitate a complete analysis of Hospira's results of operations,
    particularly in evaluating performance over time. Management uses these
    Non-GAAP financial measures internally in financial planning, to monitor
    business unit performance, and in evaluating management performance.
    Refer to Hospira's filing on Form 8-K of today's date for additional
    information.
    (2) Net sales less Cost of products sold.



                                   Hospira, Inc.
                       Condensed Consolidated Balance Sheets
                                    (Unaudited)
                               (dollars in millions)


                                                       March 31,  December 31,
                        Assets                           2009         2008
                                                       --------     --------

    Current Assets:
      Cash and cash equivalents                          $529.4       $483.8
      Trade receivables, less allowances of
       $7.6 in 2009 and $6.7 in 2008                      553.0        583.4
      Inventories                                         834.8        830.5
      Deferred income taxes                               176.8        172.2
      Prepaid expenses and other current assets            45.2         35.7
      Other receivables                                    63.1         43.7
                                                       --------     --------
          Total Current Assets                          2,202.3      2,149.3
                                                       --------     --------
    Property and equipment, net                         1,177.1      1,192.1
    Intangible assets, net                                388.9        404.4
    Goodwill                                            1,157.6      1,167.4
    Deferred income taxes                                  68.4         70.1
    Investments                                            38.2         37.6
    Other assets                                           53.2         53.2
                                                       --------     --------
          Total Assets                                 $5,085.7     $5,074.1
                                                       ========     ========

                   Liabilities and Shareholders' Equity
    Current Liabilities:
      Short-term borrowings                              $704.1       $338.3
      Trade accounts payable                              216.6        231.5
      Salaries, wages and commissions                     107.3        144.7
      Deferred income taxes                                 1.4          1.5
      Other accrued liabilities                           342.6        331.5
                                                       --------     --------
          Total Current Liabilities                     1,372.0      1,047.5
                                                       --------     --------
    Long-term debt                                      1,457.0      1,834.0
    Deferred income taxes                                  23.8         25.2
    Post-retirement obligations                           194.9        195.5
    Other long-term liabilities                            96.1        195.5
    Commitments and Contingencies
                                                       --------     --------
    Total Shareholders' Equity                          1,941.9      1,776.4
                                                       --------     --------
    Total Liabilities and Shareholders' Equity         $5,085.7     $5,074.1
                                                       ========     ========



                                  Hospira, Inc.
                 Condensed Consolidated Statements of Cash Flows
                                   (Unaudited)
                              (dollars in millions)

                                                            Three Months Ended
                                                                March  31,
                                                            -----------------
                                                             2009       2008
                                                            ------     ------
    Cash Flow From Operating Activities:

      Net income                                            $165.5      $65.4
      Adjustments to reconcile net income to net cash
       from operating activities-
        Depreciation                                          41.2       47.1
        Amortization of intangible assets                     14.7       16.9
        Stock-based compensation expense                      13.1       14.4
        Deferred income tax and other tax adjustments        (89.4)     (11.5)
      Changes in assets and liabilities-
        Trade receivables                                     20.0      (13.6)
        Inventories                                          (11.5)     (24.8)
        Prepaid expenses and other assets                    (13.1)      11.4
        Trade accounts payable                               (14.2)       6.1
        Other liabilities                                    (41.7)     (47.8)
      Other, net                                               4.7        9.9
                                                            ------     ------
        Net Cash Provided by Operating Activities             89.3       73.5
                                                            ------     ------

    Cash Flow From Investing Activities:

      Capital expenditures (including instruments placed
       with or leased to customers)                          (33.8)     (42.9)
      Payments for contingent consideration                   (7.1)         -
      Purchases of intangibles and other investments          (3.0)     (38.2)
                                                            ------     ------
        Net Cash Used in Investing Activities                (43.9)     (81.1)
                                                            ------     ------

    Cash Flow From Financing Activities:

      Repayment of long-term debt                             (5.0)     (25.0)
      Other borrowings, net                                   (0.7)       5.0
      Excess tax benefit from stock-based compensation
       arrangements                                              -        0.8
      Proceeds from stock options exercised                   12.6       12.3
                                                            ------     ------
        Net Cash Provided by (Used in) Financing Activities    6.9       (6.9)
                                                            ------     ------

    Effect of exchange rate changes on cash and cash
     equivalents                                              (6.7)       5.5
                                                            ------     ------

    Net change in cash and cash equivalents                   45.6       (9.0)
    Cash and cash equivalents at beginning of period         483.8      241.1
                                                            ------     ------
    Cash and cash equivalents at end of period              $529.4     $232.1
                                                            ======     ======

    Supplemental Cash Flow Information:

    Cash paid during the period-
      Interest                                               $33.1      $38.7
      Income taxes, net of refunds                            $9.9       $6.7



                                 Hospira, Inc.
                           Net Sales by Product Line
                                  (Unaudited)
                             (dollars in millions)


                                             Three Months Ended March 31,
                                         -----------------------------------
                                                         % Change   % Change
                                                        at Actual  at Constant
                                          2009     2008    Rates      Rates
                                         ------   ------   -----      -----
    Americas--
    Pharmaceuticals
       Specialty Injectables             $333.1   $340.7    (2.2)%     (0.4)%
       Other Pharma                       137.8    121.9    13.0 %     15.7 %
                                         ------   ------
                                          470.9    462.6     1.8 %      3.8 %
    Devices
       Medication Management Systems      121.4    118.1     2.8 %      5.9 %
       Other Devices                       92.4     93.5    (1.2)%      1.1 %
                                         ------   ------
                                          213.8    211.6     1.0 %      3.8 %

    Total Americas                        684.7    674.2     1.6 %      3.9 %

    Europe, Middle East & Africa--
    Pharmaceuticals
       Specialty Injectables               57.6     78.3   (26.4)%    (12.1)%
       Other Pharma                        27.7     36.6   (24.3)%     (8.5)%
                                         ------   ------
                                           85.3    114.9   (25.8)%    (11.0)%
    Devices
       Medication Management Systems       19.1     20.4    (6.4)%      9.0 %
       Other Devices                       16.8     17.5    (4.0)%     11.8 %
                                         ------   ------
                                           35.9     37.9    (5.3)%     10.3 %

    Total Europe, Middle East & Africa    121.2    152.8   (20.7)%     (5.7)%

    Asia Pacific--
    Pharmaceuticals
       Specialty Injectables               39.0     45.6   (14.5)%      7.7 %
       Other Pharma                         3.6      4.1   (12.2)%     17.1 %
                                         ------   ------
                                           42.6     49.7   (14.3)%      8.5%
    Devices
       Medication Management Systems        4.7      5.7   (17.5)%     (4.0)%
       Other Devices                        6.5      6.3     3.2%      13.9 %
                                         ------   ------
                                           11.2     12.0    (6.7)%      5.3 %

    Total Asia Pacific                     53.8     61.7   (12.8)%      7.9 %

                                         ------   ------
    Net Sales                            $859.7   $888.7    (3.3)%      2.4 %
                                         ======   ======

    Global--
    Pharmaceuticals
       Specialty Injectables             $429.7   $464.6    (7.5)%     (1.6)%
       Other Pharma                       169.1    162.6     4.0 %     10.3 %
                                         ------   ------
                                          598.8    627.2    (4.5)%      1.5 %

    Devices
       Medication Management Systems      145.2    144.2     0.7 %      6.0 %
       Other Devices                      115.7    117.3    (1.4)%      3.3 %
                                         ------   ------
                                          260.9    261.5    (0.2)%      4.8 %

                                         ------   ------
    Total Global                         $859.7   $888.7    (3.3)%      2.4 %
                                         ======   ======



                                   Hospira, Inc.
                                Segment Information
                                    (Unaudited)
                               (dollars in millions)

                                     Three Months Ended March 31,
                      --------------------------------------------------------
                         Net Sales             Income from Operations
                      --------------       %     -----------------        %
                       2009     2008     Change   2009       2008       Change
                      ------   ------    ------  ------     ------      ------
    Americas          $684.7   $674.2     1.6 %  $141.6  A  $136.3  A    3.9 %
    Europe, Middle
     East & Africa     121.2    152.8   (20.7)%     4.2  B     4.5  B   (6.7)%
    Asia Pacific        53.8     61.7   (12.8)%     2.7  C     2.1  C   28.6 %
                      ------   ------            ------     ------

    Total reportable
     segments         $859.7   $888.7    (3.3)%   148.5      142.9       3.9 %
                      ======   ======

    Corporate
     functions                                    (20.7) D   (16.8) D   23.2 %
    Stock-based
     compensation                                 (13.1)     (14.4)     (9.0)%
                                                 ------     ------
    Income from
     operations                                   114.7      111.7       2.7 %
    Interest expense
     and other
     income, net                                  (26.6)     (27.3)     (2.6)%
                                                 ------     ------

    Income before
     income taxes                                 $88.1      $84.4       4.4 %
                                                 ======     ======


    Included in the reported Income before income
     taxes above, are the following charges:

    A -- Americas
      Project Fuel restructuring and
       optimization                                $7.6       $  -
      Integration-related                             -        0.4
      Amortization of Mayne Pharma
       intangible assets                            4.5        5.2
      Facilities restructuring and
       optimization                                11.7        7.8
                                                 ------     ------
    Total Americas                                 23.8       13.4

    B --  Europe, Middle East & Africa
      Project Fuel restructuring and
       optimization                                 0.2          -
      Integration-related                             -        5.4
      Amortization of Mayne Pharma
       intangible assets                            5.0        5.8
                                                 ------     ------
    Total Europe, Middle East & Africa              5.2       11.2

    C --  Asia Pacific
      Project Fuel restructuring and
       optimization                                 0.5          -
      Integration-related                             -        1.6
      Amortization of Mayne Pharma
       intangible assets                            3.5        4.7
                                                 ------     ------
    Total Asia Pacific                              4.0        6.3

    D --  Corporate functions
      Project Fuel restructuring and
       optimization                                 2.2          -
      Integration-related                             -        2.6
                                                 ------     ------
    Total Corporate functions                       2.2        2.6
                                                 ------     ------
    Total                                         $35.2      $33.5
                                                 ======     ======


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Hospira to Host Conference Call for First-Quarter 2009 Results
2. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
3. Hospira Expands Board of Directors
4. Hospira Reports Fourth-Quarter and Full-Year 2008 Results
5. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
6. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
7. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
8. Hospira Names Ken Meyers to Lead Human Resources
9. Hospira Reports Third-Quarter 2008 Results
10. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
11. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a trusted name in ... trial program for all of the company’s desktop riser products. A simple application ... experience. , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, ... ... today, featuring an inspirational interview of two ostomy patients, standing as living proof ... million people suffer from digestive diseases and issues that spike around the holidays. ...
(Date:12/2/2016)... Hawaii (PRWEB) , ... December 02, 2016 , ... ... 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering ... in the field of pain management. , The demand for supplemental training ...
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Spain , Dec. 2, 2016 In ... natural sources apart from those derived from C. sativa, ... the Universita` di Napoli Federico II , the ... created the first comprehensive, critical, integrated and unified inventory ... The article focuses on the remarkable chemical and ...
(Date:12/2/2016)... Dec. 2, 2016  The Addiction Treatment Advisory ... of Managed Care Pharmacy (AMCP), has released detailed ... address the opioid addiction crisis, including through improved ... ATAG,s newly released paper, "The Role ... Naloxone," addresses many issues around gaps and barriers ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, LLC ... Pharmaceutical Specialties, Inc. ("PSI").  The combination of Texas ... Georgia -based PSI bring together both company,s clinical expertise ... and payers an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: